Normal insulin sensitivity of the islets of Langerhans in obese subjects with resistance to its glucoregulatory actions

I. Klimes, M. Nagulesparan, B. Vasquez, H. Hidaka, Roger H Unger

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The ability of varying levels of circulating insulin to suppress α- and β-cell secretion was assessed by plasma glucagon and C-peptide measurement in 6 obese and 6 nonobese subjects maintained in a euglycemic state, with an insulin concentration elevated by 10, 20, or 100 μU/ml above basal levels by a primed-continuous infusion of insulin. The 10μU/ml increase did not suppress C-peptide levels significantly in either group. However, incremental increases in plasma insulin of approximately 20 and 100 μU/ml above basal suppressed plasma C-peptide by 0.27 ± 0.14 and 0.53 ± 0.07 pmol/ml, respectively, in the obese subjects (14% and 31% of the basal values of 2.20 ± 0.18 and 2.19 ± 0.26 pmol/ml, respectively) and by 0.16 ± 0.06 and 0.17 ± 0.06 pmol/ml in the nonobese subjects (20% and 25% the basal values of 0.74 ± 0.11 and 0.78 ± 0.11 pmol/ml, respectively). Plasma glucagon levels were suppressed to a similar degree in each group in a dose-related manner during both the 20-μU/ml and 100-μU/ml clamps. We were unable to identify an increment of insulin that suppressed C-peptide and/or glucagon in one group but not in another. These data demonstrate inhibition of α- and β-cell secretion by insulin within its physiologic range in both non-obese and obese man, and exclude insulin resistance of α- and β-cells in obese individuals. However, despite their much higher insulin levels before and during the insulin infusions, obese subjects had C-peptide levels that, at all times, were 3-3.5-fold higher than those of the nonobese subjects. This is consistent with a greater number and/or a higher secretory activity of β-cells in the obese subjects.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalDiabetes
Volume33
Issue number4
StatePublished - 1984

Fingerprint

Islets of Langerhans
Insulin Resistance
C-Peptide
Insulin
Glucagon

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Normal insulin sensitivity of the islets of Langerhans in obese subjects with resistance to its glucoregulatory actions. / Klimes, I.; Nagulesparan, M.; Vasquez, B.; Hidaka, H.; Unger, Roger H.

In: Diabetes, Vol. 33, No. 4, 1984, p. 305-310.

Research output: Contribution to journalArticle

Klimes, I. ; Nagulesparan, M. ; Vasquez, B. ; Hidaka, H. ; Unger, Roger H. / Normal insulin sensitivity of the islets of Langerhans in obese subjects with resistance to its glucoregulatory actions. In: Diabetes. 1984 ; Vol. 33, No. 4. pp. 305-310.
@article{cbfb0887e2134f239fd8e20bb3a31c16,
title = "Normal insulin sensitivity of the islets of Langerhans in obese subjects with resistance to its glucoregulatory actions",
abstract = "The ability of varying levels of circulating insulin to suppress α- and β-cell secretion was assessed by plasma glucagon and C-peptide measurement in 6 obese and 6 nonobese subjects maintained in a euglycemic state, with an insulin concentration elevated by 10, 20, or 100 μU/ml above basal levels by a primed-continuous infusion of insulin. The 10μU/ml increase did not suppress C-peptide levels significantly in either group. However, incremental increases in plasma insulin of approximately 20 and 100 μU/ml above basal suppressed plasma C-peptide by 0.27 ± 0.14 and 0.53 ± 0.07 pmol/ml, respectively, in the obese subjects (14{\%} and 31{\%} of the basal values of 2.20 ± 0.18 and 2.19 ± 0.26 pmol/ml, respectively) and by 0.16 ± 0.06 and 0.17 ± 0.06 pmol/ml in the nonobese subjects (20{\%} and 25{\%} the basal values of 0.74 ± 0.11 and 0.78 ± 0.11 pmol/ml, respectively). Plasma glucagon levels were suppressed to a similar degree in each group in a dose-related manner during both the 20-μU/ml and 100-μU/ml clamps. We were unable to identify an increment of insulin that suppressed C-peptide and/or glucagon in one group but not in another. These data demonstrate inhibition of α- and β-cell secretion by insulin within its physiologic range in both non-obese and obese man, and exclude insulin resistance of α- and β-cells in obese individuals. However, despite their much higher insulin levels before and during the insulin infusions, obese subjects had C-peptide levels that, at all times, were 3-3.5-fold higher than those of the nonobese subjects. This is consistent with a greater number and/or a higher secretory activity of β-cells in the obese subjects.",
author = "I. Klimes and M. Nagulesparan and B. Vasquez and H. Hidaka and Unger, {Roger H}",
year = "1984",
language = "English (US)",
volume = "33",
pages = "305--310",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Normal insulin sensitivity of the islets of Langerhans in obese subjects with resistance to its glucoregulatory actions

AU - Klimes, I.

AU - Nagulesparan, M.

AU - Vasquez, B.

AU - Hidaka, H.

AU - Unger, Roger H

PY - 1984

Y1 - 1984

N2 - The ability of varying levels of circulating insulin to suppress α- and β-cell secretion was assessed by plasma glucagon and C-peptide measurement in 6 obese and 6 nonobese subjects maintained in a euglycemic state, with an insulin concentration elevated by 10, 20, or 100 μU/ml above basal levels by a primed-continuous infusion of insulin. The 10μU/ml increase did not suppress C-peptide levels significantly in either group. However, incremental increases in plasma insulin of approximately 20 and 100 μU/ml above basal suppressed plasma C-peptide by 0.27 ± 0.14 and 0.53 ± 0.07 pmol/ml, respectively, in the obese subjects (14% and 31% of the basal values of 2.20 ± 0.18 and 2.19 ± 0.26 pmol/ml, respectively) and by 0.16 ± 0.06 and 0.17 ± 0.06 pmol/ml in the nonobese subjects (20% and 25% the basal values of 0.74 ± 0.11 and 0.78 ± 0.11 pmol/ml, respectively). Plasma glucagon levels were suppressed to a similar degree in each group in a dose-related manner during both the 20-μU/ml and 100-μU/ml clamps. We were unable to identify an increment of insulin that suppressed C-peptide and/or glucagon in one group but not in another. These data demonstrate inhibition of α- and β-cell secretion by insulin within its physiologic range in both non-obese and obese man, and exclude insulin resistance of α- and β-cells in obese individuals. However, despite their much higher insulin levels before and during the insulin infusions, obese subjects had C-peptide levels that, at all times, were 3-3.5-fold higher than those of the nonobese subjects. This is consistent with a greater number and/or a higher secretory activity of β-cells in the obese subjects.

AB - The ability of varying levels of circulating insulin to suppress α- and β-cell secretion was assessed by plasma glucagon and C-peptide measurement in 6 obese and 6 nonobese subjects maintained in a euglycemic state, with an insulin concentration elevated by 10, 20, or 100 μU/ml above basal levels by a primed-continuous infusion of insulin. The 10μU/ml increase did not suppress C-peptide levels significantly in either group. However, incremental increases in plasma insulin of approximately 20 and 100 μU/ml above basal suppressed plasma C-peptide by 0.27 ± 0.14 and 0.53 ± 0.07 pmol/ml, respectively, in the obese subjects (14% and 31% of the basal values of 2.20 ± 0.18 and 2.19 ± 0.26 pmol/ml, respectively) and by 0.16 ± 0.06 and 0.17 ± 0.06 pmol/ml in the nonobese subjects (20% and 25% the basal values of 0.74 ± 0.11 and 0.78 ± 0.11 pmol/ml, respectively). Plasma glucagon levels were suppressed to a similar degree in each group in a dose-related manner during both the 20-μU/ml and 100-μU/ml clamps. We were unable to identify an increment of insulin that suppressed C-peptide and/or glucagon in one group but not in another. These data demonstrate inhibition of α- and β-cell secretion by insulin within its physiologic range in both non-obese and obese man, and exclude insulin resistance of α- and β-cells in obese individuals. However, despite their much higher insulin levels before and during the insulin infusions, obese subjects had C-peptide levels that, at all times, were 3-3.5-fold higher than those of the nonobese subjects. This is consistent with a greater number and/or a higher secretory activity of β-cells in the obese subjects.

UR - http://www.scopus.com/inward/record.url?scp=0021327122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021327122&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 305

EP - 310

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -